The glucagon-like peptide-1 agonists market is currently ruled by two names — Eli Lilly and Novo Nordisk — who together hold close to 94% of global share. That kind of concentration makes glp 1 agonist market share tracking almost a two-company exercise today, but the picture is shifting fast. Upcoming patent expiries, biosimilar entrants, and a widening pipeline mean the glp-1 agonist sales story of the next decade will look very different from 2024's near-duopoly. For anyone running glp 1 agonist market analysis, this transition period is exactly where the interesting competitive movement will happen.

Sizing the Opportunity: GLP-1 Market Size and Growth

Every glp 1 market size estimate now has to account for obesity, not just diabetes. With roughly 32 million US adults living with type 2 diabetes and an estimated 120 million adults and children meeting obesity criteria, the glp-1 market analysis community has had to repeatedly revise addressable-population assumptions upward. This is the backdrop for most glp-1 market analytics data models projecting an 11-year forecast window through 2036 — a horizon long enough to capture both patent cliffs and next-generation launches.

Semaglutide, Tirzepatide, and the Broader GLP-1 Analogue Landscape

Within the glp-1 analogues market, semaglutide (Ozempic, Rybelsus, Wegovy) remains the volume leader at roughly 58% share, while tirzepatide (Mounjaro, Zepbound) — a dual GIP/GLP-1 agonist — posted 2025 sales of USD 36.51 billion combined, with Zepbound alone growing about 44% year-over-year into Q2 2026. Eli Lilly's oral entrant Foundayo (orforglipron), approved in April 2026, has meanwhile reset expectations for the oral glp-1/glucagon dual agonist development 2025 conversation by removing food and water restrictions typical of earlier oral incretins.

Who's Leading: GLP-1 Companies and Pipeline Assets

A current leading glp-1 drug market companies list runs through Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Zealand Pharma, and AstraZeneca. Among leading pharma manufacturers advancing glp-1 agonists for obesity clinical development, Boehringer Ingelheim's survodutide (BI 456906) stands out after Phase III data showed up to 34% visceral fat reduction and 63.1% liver fat reduction in obesity patients. Novo Nordisk's CagriSema — a fixed-dose cagrilintide/semaglutide combination — and Eli Lilly's retatrutide round out the assets most glp-1 therapeutic analytics coverage watches closely, with retatrutide's Phase III package now complete for obesity, sleep apnea, and knee osteoarthritis submissions.

Competitive Monitoring and Indirect Competitor Analysis

For teams asked to evaluate the pharmaceuticals company ozempic on glp-1 efficacy / effectiveness, the relevant benchmarks now include not just glycemic control but cardiovascular event reduction and kidney disease progression, both part of Ozempic's expanded label. Similarly, to evaluate the diabetes & obesity pharmaceuticals company trulicity on indirect competitor monitoring, or to evaluate the pharmaceuticals company byetta on amgen and glp-1, analysts increasingly weigh legacy GLP-1 agents against newer dual- and multi-agonist mechanisms rather than against each other alone.

What's Next in the GLP-1 Pipeline

Beyond the current approved glp-1 receptor agonists list 2026, the glp-1 gip glucagon amylin mc4r pyy peptide drugs pipeline 2019-2026 reflects a broader industry push into multi-receptor agonism. This is the core of most oral glp-1 glucagon dual agonist development 2025 and which pharmaceutical companies have the largest market share in the prescription glp-1 receptor agonist weight loss drug space research questions — the next leg of growth depends less on new molecules targeting GLP-1 alone and more on combination biology that layers in glucagon, GIP, or amylin pathways.

Market Access, Reimbursement, and Long-Term Outlook

Pricing remains the single biggest lever in beste glp-1 receptoragonister producenter discussions worldwide, with programs like Novo Nordisk's patient-assistance initiatives illustrating how access strategy is now inseparable from commercial strategy. As emerging commercial opportunities in pharmaceuticals for peptide therapeutics and glp1 medicines in the a$ market continue to surface, expect competition to increasingly hinge on convenience (oral vs. injectable), tolerability, and breadth of approved indications rather than glycemic efficacy alone — a trend that will define the glp-1 agonists industry through 2036.

Latest Reports Offered by Delveinsight

ibi363 mechanism of action, jak kinase inhibitor alopecia, dupixent copd, janus kinase inhibitors, fibroblast growth factors, lysosomal storage disorder, sleep technologies, lysosomal storage disorders, neiman pick, lysosomal storage disorder, bispecific antibody news, the lepr, dawnzera, egfr inhibitors, ai diagnostics, nanorobotics, hutchinson gilford progeria disease, immunohistochemistry, asmd, parenteral feeding , sodium channel antagonist, phosphodiesterase 4, ai pathology news, medications for uc, amyotrophic lateral sclerosis market, complement inhibitors, point-of-care diagnostics news, digital therapeutics, what is alternative medicine, definition of health disparity, b7-h3, digital therapeutics news, amyotrophic lateral sclerosis market, pecoma cancer, digital pathology news today, sglt2 inhibitor list, hgps disease, what are nanobots, alternative medicine is an alternative to what, human papillomavirus 16

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com